These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

168 related items for PubMed ID: 20838440

  • 1. Cancer cells acquire mitotic drug resistance properties through beta I-tubulin mutations and alterations in the expression of beta-tubulin isotypes.
    Cheung CH, Wu SY, Lee TR, Chang CY, Wu JS, Hsieh HP, Chang JY.
    PLoS One; 2010 Sep 03; 5(9):e12564. PubMed ID: 20838440
    [Abstract] [Full Text] [Related]

  • 2. Survivin counteracts the therapeutic effect of microtubule de-stabilizers by stabilizing tubulin polymers.
    Cheung CH, Chen HH, Kuo CC, Chang CY, Coumar MS, Hsieh HP, Chang JY.
    Mol Cancer; 2009 Jul 03; 8():43. PubMed ID: 19575780
    [Abstract] [Full Text] [Related]

  • 3. An antimitotic and antivascular agent BPR0L075 overcomes multidrug resistance and induces mitotic catastrophe in paclitaxel-resistant ovarian cancer cells.
    Wang X, Wu E, Wu J, Wang TL, Hsieh HP, Liu X.
    PLoS One; 2013 Jul 03; 8(6):e65686. PubMed ID: 23762410
    [Abstract] [Full Text] [Related]

  • 4. Novel mutations involving βI-, βIIA-, or βIVB-tubulin isotypes with functional resemblance to βIII-tubulin in breast cancer.
    Wang W, Zhang H, Wang X, Patterson J, Winter P, Graham K, Ghosh S, Lee JC, Katsetos CD, Mackey JR, Tuszynski JA, Wong GK, Ludueña RF.
    Protoplasma; 2017 May 03; 254(3):1163-1173. PubMed ID: 27943021
    [Abstract] [Full Text] [Related]

  • 5. Molecular dynamics simulation and free energy landscape methods in probing L215H, L217R and L225M βI-tubulin mutations causing paclitaxel resistance in cancer cells.
    Tripathi S, Srivastava G, Sharma A.
    Biochem Biophys Res Commun; 2016 Aug 05; 476(4):273-279. PubMed ID: 27233604
    [Abstract] [Full Text] [Related]

  • 6. βI-tubulin mutations in the laulimalide/peloruside binding site mediate drug sensitivity by altering drug-tubulin interactions and microtubule stability.
    Kanakkanthara A, Rowe MR, Field JJ, Northcote PT, Teesdale-Spittle PH, Miller JH.
    Cancer Lett; 2015 Sep 01; 365(2):251-60. PubMed ID: 26052091
    [Abstract] [Full Text] [Related]

  • 7. Microtubule dynamics, mitotic arrest, and apoptosis: drug-induced differential effects of betaIII-tubulin.
    Gan PP, McCarroll JA, Po'uha ST, Kamath K, Jordan MA, Kavallaris M.
    Mol Cancer Ther; 2010 May 01; 9(5):1339-48. PubMed ID: 20442307
    [Abstract] [Full Text] [Related]

  • 8. DTA0100, dual topoisomerase II and microtubule inhibitor, evades paclitaxel resistance in P-glycoprotein overexpressing cancer cells.
    Podolski-Renić A, Banković J, Dinić J, Ríos-Luci C, Fernandes MX, Ortega N, Kovačević-Grujičić N, Martín VS, Padrón JM, Pešić M.
    Eur J Pharm Sci; 2017 Jul 15; 105():159-168. PubMed ID: 28502672
    [Abstract] [Full Text] [Related]

  • 9. Resistance to peloruside A and laulimalide: functional significance of acquired βI-tubulin mutations at sites important for drug-tubulin binding.
    Kanakkanthara A, Eras J, Northcote PT, Cabral F, Miller JH.
    Curr Cancer Drug Targets; 2014 Jul 15; 14(1):79-90. PubMed ID: 24245693
    [Abstract] [Full Text] [Related]

  • 10. Zerumbone, a cyclic sesquiterpene, exerts antimitotic activity in HeLa cells through tubulin binding and exhibits synergistic activity with vinblastine and paclitaxel.
    Ashraf SM, Sebastian J, Rathinasamy K.
    Cell Prolif; 2019 Mar 15; 52(2):e12558. PubMed ID: 30525278
    [Abstract] [Full Text] [Related]

  • 11. Discovery of thalicthuberine as a novel antimitotic agent from nature that disrupts microtubule dynamics and induces apoptosis in prostate cancer cells.
    Levrier C, Rockstroh A, Gabrielli B, Kavallaris M, Lehman M, Davis RA, Sadowski MC, Nelson CC.
    Cell Cycle; 2018 Mar 15; 17(5):652-668. PubMed ID: 28749250
    [Abstract] [Full Text] [Related]

  • 12. Delineating the interaction of combretastatin A-4 with αβ tubulin isotypes present in drug resistant human lung carcinoma using a molecular modeling approach.
    Kumbhar BV, Bhandare VV, Panda D, Kunwar A.
    J Biomol Struct Dyn; 2020 Feb 15; 38(2):426-438. PubMed ID: 30831055
    [Abstract] [Full Text] [Related]

  • 13. Alterations of beta-tubulin isotypes in breast cancer cells resistant to docetaxel.
    Shalli K, Brown I, Heys SD, Schofield AC.
    FASEB J; 2005 Aug 15; 19(10):1299-301. PubMed ID: 15946994
    [Abstract] [Full Text] [Related]

  • 14. Multiple microtubule alterations are associated with Vinca alkaloid resistance in human leukemia cells.
    Kavallaris M, Tait AS, Walsh BJ, He L, Horwitz SB, Norris MD, Haber M.
    Cancer Res; 2001 Aug 01; 61(15):5803-9. PubMed ID: 11479219
    [Abstract] [Full Text] [Related]

  • 15. A semisynthetic taxane Yg-3-46a effectively evades P-glycoprotein and β-III tubulin mediated tumor drug resistance in vitro.
    Cai P, Lu P, Sharom FJ, Fang WS.
    Cancer Lett; 2013 Dec 01; 341(2):214-23. PubMed ID: 23941826
    [Abstract] [Full Text] [Related]

  • 16. BetaIII-tubulin induces paclitaxel resistance in association with reduced effects on microtubule dynamic instability.
    Kamath K, Wilson L, Cabral F, Jordan MA.
    J Biol Chem; 2005 Apr 01; 280(13):12902-7. PubMed ID: 15695826
    [Abstract] [Full Text] [Related]

  • 17. A highly epothilone B-resistant A549 cell line with mutations in tubulin that confer drug dependence.
    Yang CP, Verdier-Pinard P, Wang F, Lippaine-Horvath E, He L, Li D, Höfle G, Ojima I, Orr GA, Horwitz SB.
    Mol Cancer Ther; 2005 Jun 01; 4(6):987-95. PubMed ID: 15956256
    [Abstract] [Full Text] [Related]

  • 18. Neuronal-associated microtubule proteins class III beta-tubulin and MAP2c in neuroblastoma: role in resistance to microtubule-targeted drugs.
    Don S, Verrills NM, Liaw TY, Liu ML, Norris MD, Haber M, Kavallaris M.
    Mol Cancer Ther; 2004 Sep 01; 3(9):1137-46. PubMed ID: 15367708
    [Abstract] [Full Text] [Related]

  • 19. Regulation of β-tubulin isotypes by micro-RNA 100 in MCF7 breast cancer cells.
    Lobert S, Jefferson B, Morris K.
    Cytoskeleton (Hoboken); 2011 Jun 01; 68(6):355-62. PubMed ID: 21634028
    [Abstract] [Full Text] [Related]

  • 20. Class I beta-tubulin mutations in 2-methoxyestradiol-resistant acute lymphoblastic leukemia cells: implications for drug-target interactions.
    Liaw TY, Salam NK, McKay MJ, Cunningham AM, Hibbs DE, Kavallaris M.
    Mol Cancer Ther; 2008 Oct 01; 7(10):3150-9. PubMed ID: 18852118
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.